BACKGROUND:The objective of this article was to report the results from a randomized clinical trial comparing intensity-modulated radiotherapy (IMRT) with 3-dimensonal conformal radiotherapy (3DCRT) for the treatment of prostate cancer on a hypofractionated schedule. METHODS: The authors randomly assigned 215 men who had localized prostate cancer to receive hypofractionated radiotherapy to a total dose of 70 grays (Gy) in 25 fractions (at 2.8 Gy per fraction) using either IMRT or 3DCRT. Acute and late gastrointestinal (GI) and genitourinary (GU) toxicity were prospectively evaluated according to modified Radiation Therapy Oncology Group criteria. Biochemical control was defined according to the Phoenix criteria (prostate-specific antigen nadir 1 2 ng/mL). RESULTS: In total, 215 patients were enrolled in the IMRT group (n 5 109) or the 3DCRT group (n 5 106). The 3DCRT arm had a 27% rate of grade 2 acute GU toxicity compared with a 9% rate in the IMRT arm (P 5.001) and a 24% rate of grade 2 acute GI toxicity compared with a 7% rate in the IMRT arm (P 5.001). The maximal rate of grade 2 late GU toxicity during the entire period of follow-up was 3.7% in the IMRT group versus 12.3% in the 3DCRT group (P 5.02). The maximal rate of grade 2 late GI toxicity during the entire follow-up was 6.4% in the IMRT group versus 21.7% in the 3DCRT group (P 5.001). The 5-year rate of freedom from biochemical failure was 95.4% in the IMRT arm and 94.3% in the 3DCRT arm (P 5.678). CONCLUSIONS: IMRT reduced the delivery of significant radiation doses to the bladder and rectum using a similar target volume. This dosimetric advantage resulted in a lower rate of acute/late grade 2 GI and GU toxicity for IMRT compared with 3DCRT.

a b s t r a c tAim: To report the treatment results of a retrospective cohort of prostate cancer patients treated with Hypo-RT with a high equivalent biological effective dose (BED).Background: Hypofractionated radiotherapy (Hypo-RT) has gained popularity and interest in

WBRT plus SRS was an independent prognostic factor for survival. However, the combined treatment appears to be justified only in patients with RPA I and lesion volume ≤5 cm 3, independently of the number of lesions.